Retatrutide Dosage: Trial Titration Schedule, Dosing Chart, and What It Means for Real-World Use
Last updated: August 6, 2026
Retatrutide does not yet have an FDA-approved dose. In clinical trials, participants generally start at 2 mg once weekly and increase gradually through 4 mg and 8 mg toward a maintenance dose of 9 mg or 12 mg.
Retatrutide does not yet have an FDA-approved dose. It is an investigational medication still in Phase 3 clinical trials, so there is no official prescribing label and no approved dosing instructions. What does exist — and what nearly everyone searching for "retatrutide dosage" is looking for — is the dosing schedule used in Eli Lilly's clinical trials, and what that predicts about how the drug will be prescribed if and when it is approved.
In the trials, retatrutide is given as a once-weekly subcutaneous injection, and participants do not start at their target dose. They begin low and step up over several months. Across the Phase 2 obesity study and the Phase 3 TRIUMPH program, the pattern is consistent: start at 2 mg weekly, then escalate through 4 mg and 8 mg, up to a maintenance dose of 9 mg or 12 mg, over a minimum of about 16 weeks. The reason for the slow climb is tolerability — GI side effects are most intense right after each dose increase, and a gradual schedule keeps them manageable.
This page is educational information about how the drug is studied — not medical advice, and not a prescribing instruction.
| Phase | Weekly dose | Typical duration | Purpose |
|---|---|---|---|
| Starting dose | 2 mg | ~4 weeks | Introduce the drug, minimize early nausea |
| Escalation step 1 | 4 mg | ~4 weeks | Begin building toward a therapeutic dose |
| Escalation step 2 | 8 mg | ~4 weeks | Approach the maintenance range |
| Maintenance (A) | 9 mg | Ongoing | Assigned maintenance dose in some trial arms |
| Maintenance (B) | 12 mg | Ongoing | Highest tested dose; largest weight-loss effect |
Total time from first injection to full maintenance dose is typically 16 to 24 weeks, depending on tolerability. Patients with significant side effects may stay at a step longer, or step back down temporarily, before continuing.
The slow climb is deliberate. GI adverse events — nausea, vomiting, diarrhea, constipation — are dose-dependent and concentrated in the days and weeks after each increase. Starting a patient directly at 12 mg would produce side effects severe enough that many would stop before reaching benefit. This relationship between side effects and retatrutide dosage is one reason managing side effects during titration matters. Stepping up over months keeps each change tolerable, which keeps people on the drug long enough to see results. This is the same logic used for tirzepatide (starts at 2.5 mg) and semaglutide (starts at 0.25 mg).
The introductory dose gives the body time to begin adapting.
Each step builds toward the assigned maintenance range.
Slower escalation helps reduce treatment-limiting gastrointestinal effects.
of participants at the 12 mg dose lost 30% or more of their body weight.
Higher doses produced more weight loss, which is why the 12 mg dose gets the most attention. In the Phase 2 obesity trial (48 weeks), participants at 12 mg lost an average of about 24.2% of body weight. In the Phase 3 TRIUMPH-1 obesity trial (reported 2026), the 12 mg dose produced roughly 28.3% at 80 weeks (~70 lb) and 30.3% at 104 weeks (~85 lb), with 45.3% of participants losing 30% or more. The maintenance dose reached is a major driver of the result — which is why understanding how dose relates to weight loss matters so much when looking at how weight-loss results develop over time.
Once approved (projected 2027–2028), dosing in practice is expected to mirror the trials. Expect to start low (likely 2 mg) and titrate up over four to six months; side effects will be most noticeable in the first eight weeks and around each step; and the maintenance dose an individual settles on may not be the maximum — many patients on tirzepatide and semaglutide stabilize at an intermediate dose. None of this substitutes for an eventual FDA label or a prescribing clinician.
Retatrutide Dosage and Compounded or "Research" Products
Because retatrutide is not approved, it cannot be legally prescribed or, in the ordinary sense, compounded for general weight-loss use. Products marketed online as "research" retatrutide are not FDA-regulated, not verified for identity, purity, or concentration, and often arrive as a powder with no validated dosing. The neat 2/4/8/12 mg schedule cannot be assumed to apply to an unverified product of unknown strength, and self-dosing such products carries real risks.
The safest path is a medically supervised one. Cost is another important consideration when evaluating what a future approved retatrutide dosage could mean in practice. Until a dedicated access page is published, you can join the retatrutide updates list for major dosing and availability milestones.
You can also follow our retatrutide approval updates for regulatory developments.
Want the approved retatrutide dosing schedule the moment the FDA label publishes? Join our retatrutide updates list — one email per major milestone, no marketing.
Join the Retatrutide Updates ListRetatrutide is an investigational medication. It is not approved by the FDA and is not commercially available. The dosing schedules here reflect clinical trials, not approved prescribing instructions. Educational only; not medical advice. Do not attempt to dose retatrutide on your own.
What is the starting dose of retatrutide?
In clinical trials, retatrutide is typically started at 2 mg once weekly by subcutaneous injection, held for about four weeks before the first increase to limit early GI side effects. There is no FDA-approved starting dose yet.
What is the maximum dose of retatrutide?
The highest dose tested in the main trials is 12 mg once weekly, which also produced the greatest weight loss. Some arms use a 9 mg maintenance dose. The maximum approved dose will be set by the FDA label if approved.
How long does it take to reach the full retatrutide dose?
Typically 16 to 24 weeks — about four weeks each at 2 mg, 4 mg, and 8 mg, then up to 9 mg or 12 mg. Those with significant side effects may stay at a dose longer or step down temporarily.
Is retatrutide taken daily or weekly?
Retatrutide is a once-weekly subcutaneous injection in all of its major trials, the same schedule as tirzepatide and semaglutide.
Can you start retatrutide at a high dose to lose weight faster?
No. Starting high sharply increases GI side effects and, rarely, dehydration or more serious complications. Gradual titration is what lets most patients reach an effective dose without dropping out.
Is there an approved retatrutide dosing chart?
Not yet. Any chart today reflects clinical-trial schedules, not an FDA-approved label. An official chart will only exist after approval, projected for 2027–2028.